Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07669051 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a prospective, single-center, Phase II clinical study designed to explore the efficacy and safety of ivonescimab plus third-generation EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer who developed slow progression or potential progression after prior EGFR-TKI therapy.
Trial Details
NCT Number NCT07669051
Lead Sponsor Shandong Cancer Hospital and Institute
Conditions
(from sponsor)		 NSCLC (Advanced Non-small Cell Lung Cancer)
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov